An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy

Enrolling by invitationOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2038

Conditions
Duchenne Muscular Dystrophy
Interventions
GENETIC

Delandistrogene Moxeparvovec

No study medication will be provided by the sponsor during this study.

DRUG

Standard of Care

No study medication will be provided by the sponsor during this study.

Trial Locations (22)

17033

Penn State Health Milton S. Hershey Medical Center, Hershey

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

22903

University of Virginia, Charlottesville

23507

Children's Hospital of the King's Daughters, Norfolk

32827

Nemours Children's Hospital - Orlando, Orlando

33155

Nicklaus Children's Hospital, Miami

33701

All Children's Research Institute, Inc, St. Petersburg

37232

Vanderbilt University Medical Center, Nashville

38103

Le Bonheur Children's Hospital, Memphis

46202

Indiana Clinical and Translational Science Institute, Indianapolis

48109

University of Michigan, Ann Arbor

66160

University of Kansas Medical Center, Kansas City

72202

Arkansas Children's Hospital, Little Rock

76104

Cook Children's Hospital, Fort Worth

80045

University of Colorado - PPDS, Aurora

90027

Children's Hospital Los Angeles - PIN, Los Angeles

97239

OHSU Healthcare (Oregon Health and Science University), Portland

98105

Seattle Children's Hospital, Seattle

60611-2991

Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago

53715-1218

The Board of Regents of the University of Wisconsin, Madison

53226-4874

The Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY